Sort
40,608 grants matching “prostate cancer”
Phosphoinositides and Cancer Metabolism
$993,256Lewis C Cantley · Dana-Farber Cancer Inst · R35 · FY2022 · CA
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
$993,062Romonia Renee Reams · Florida Agricultural And Mechanical Univ · U54 · FY2023 · CA
Biospecimen procurement and tissue microarray manufacture for the CHTN
$992,980Christopher A. Moskaluk · University Of Virginia · UM1 · FY2020 · CA
DECODE: Diagnostic Excellence Center on Diagnostic Error
$992,942Ramin Khorasani · Brigham And Women'S Hospital · R18 · FY2022 · HS
Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy
$992,844Srinivas Sridhar · Theranano, Llc · R42 · FY2020 · CA
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research
$992,344Catherine M. Tangen · Fred Hutchinson Cancer Research Center · UM1 · FY2016 · CA
THE ROLE OF MUTATIONS IN BRCA2 AND OTHER KNOWN AND NOVEL CANCER SUSCEPTIBILITY GENES IN INHERITED RISK FOR LETHAL PROSTATE CANCER
$992,111University Of Utah · · FY2016 · Department of the Army
CHEMOPREVENTION OF FAMILIAL PROSTATE CANCER
$991,881University Of California Irvine · U19 · FY2000 · CA
Robust Predictor of Breast Cancer Risk
$991,797Harry Ostrer · Morgan And Mendel Genomics, Inc. · R42 · FY2020 · CA
Characterization of Cancer Stem Cells
$991,766William Farrar · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research
$991,495Catherine M. Tangen · Fred Hutchinson Cancer Research Center · UM1 · FY2014 · CA
Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level
$991,182Andrea Califano · Columbia University Health Sciences · U01 · FY2022 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments
$991,179Michael H Cardone · Eutropics Pharmaceuticals, Inc. · R44 · FY2018 · CA
Robust Classification Methods for Categorical Regression
$990,520Steven S Henley · Martingale Research Corporation · R44 · FY2010 · CA
DUAL-MODALITY ULTRASOUND & PHOTOACOUSTIC MOLECULAR IMAGING STRATEGIES FOR AGGRESSIVE PROSTATE CANCER DETECTION
$990,405The Pennsylvania State University · · FY2022 · Defense Health Agency
Proteomic Predictors of Clinical Outcome of Targeted Therapies in Prostate Cancer
$990,371David B Agus · Stanford University · U54 · FY2008 · CA
Bifunctional T cell receptor based immunotherapeutics
$990,016Hing C. Wong · Altor Bioscience. Llc · R44 · FY2010 · CA
EPIGENETIC CHANGES AND CLINICOPATHOLOGICAL CHARACTERIZATION OF PROSTATE CANCER FROM PATIENTS OF AFRICAN ANCESTRY.
$990,000University Of Southern California · · FY2021 · Defense Health Agency
A SYSTEMS BIOLOGY APPROACH OF LINK NUCLEAR FACTOR KAPPA B ACTIVATION WITH LETHAL PROSTATE CANCER
$989,452Dana-Farber Cancer Institute, Inc. · · FY2011 · Department of Defense
Development of synthetic sphingolipids for prostate cancer therapy
$989,405Alison Nicole McCracken · Siege Pharmaceuticals, Inc. · R44 · FY2021 · CA
THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: CLINICAL RESEARCH SITE APPLICATION
$989,026Regents Of The University Of California, San Francisco, The · · FY2018 · Department of the Army
GENOMICALLY INFORMED MORPHOLOGICAL STROMAL SIGNATURES TO PREDICT LETHAL PROSTATE CANCER
$988,740Weill Medical College Of Cornell University · · FY2025 · Defense Health Agency
Pharmacogenetic Studies
$988,591Neil E. Caporaso · Division Of Cancer Epidemiology And Genetics · ZIA · FY2010 · CA
Risk prediction methods
$988,223Mitchell H Gail · Division Of Cancer Epidemiology And Genetics · ZIA · FY2010 · CA
Novel Biguanides to Treat Type 2 Diabetes
$987,938Ken W Batchelor · Novatarg, Inc. · R44 · FY2016 · DK